WO2012074249A2 - 신규한 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 Raf키나제의 저해활성을 가지는 약학적 조성물 - Google Patents
신규한 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 Raf키나제의 저해활성을 가지는 약학적 조성물 Download PDFInfo
- Publication number
- WO2012074249A2 WO2012074249A2 PCT/KR2011/009091 KR2011009091W WO2012074249A2 WO 2012074249 A2 WO2012074249 A2 WO 2012074249A2 KR 2011009091 W KR2011009091 W KR 2011009091W WO 2012074249 A2 WO2012074249 A2 WO 2012074249A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- purin
- pyridin
- difluorophenyl
- ylamino
- sulfonamide
- Prior art date
Links
- NQISMKJSCFLCFF-UHFFFAOYSA-N COC(c([s]cc1)c1S(Nc(ccc(F)c1Nc(nccc2)c2-c2c3nc[nH]c3ncn2)c1F)(=O)=O)=O Chemical compound COC(c([s]cc1)c1S(Nc(ccc(F)c1Nc(nccc2)c2-c2c3nc[nH]c3ncn2)c1F)(=O)=O)=O NQISMKJSCFLCFF-UHFFFAOYSA-N 0.000 description 1
- NRXIQNZUPYHZJU-UHFFFAOYSA-N Cc(nc(C)[s]1)c1S(Nc(ccc(F)c1Nc(nccc2)c2-c2c3nc[nH]c3ncn2)c1F)(=O)=O Chemical compound Cc(nc(C)[s]1)c1S(Nc(ccc(F)c1Nc(nccc2)c2-c2c3nc[nH]c3ncn2)c1F)(=O)=O NRXIQNZUPYHZJU-UHFFFAOYSA-N 0.000 description 1
- AAADXMXYZRUUBD-UHFFFAOYSA-N Cc1cc(S(Nc(ccc(F)c2Nc(nccc3)c3-c3c4nc[nH]c4ncn3)c2F)(=O)=O)c(C(F)(F)F)[o]1 Chemical compound Cc1cc(S(Nc(ccc(F)c2Nc(nccc3)c3-c3c4nc[nH]c4ncn3)c2F)(=O)=O)c(C(F)(F)F)[o]1 AAADXMXYZRUUBD-UHFFFAOYSA-N 0.000 description 1
- FJDHTUKBHFXBLS-UHFFFAOYSA-N O=S(c(cccc1)c1Cl)(Nc(ccc(F)c1Nc(nccc2)c2-c2c3nc[nH]c3ncn2)c1F)=O Chemical compound O=S(c(cccc1)c1Cl)(Nc(ccc(F)c1Nc(nccc2)c2-c2c3nc[nH]c3ncn2)c1F)=O FJDHTUKBHFXBLS-UHFFFAOYSA-N 0.000 description 1
- QZRYHOXAGKASKV-UHFFFAOYSA-N O=S(c1ccc[o]1)(Nc(ccc(F)c1Nc(nccc2)c2-c2c3nc[nH]c3ncn2)c1F)=O Chemical compound O=S(c1ccc[o]1)(Nc(ccc(F)c1Nc(nccc2)c2-c2c3nc[nH]c3ncn2)c1F)=O QZRYHOXAGKASKV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention provides a novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical having inhibitory activity of Raf kinase containing the same as an active ingredient. To a composition.
- cancer is one of the most common diseases in humans and is the leading cause of death.
- many research groups have invested large sums of money to develop effective treatments for cancer.
- anticancer therapies do not act selectively on cancer cells except healthy cells, but also toxic to normal cells, and thus have undesirable effects as anti-cancer chemotherapy agents.
- anticancer therapies may be applied to targets that act on metabolic pathways or components that make up these pathways, ie expressed in cancer cells and little or no expression in healthy cells. It is desirable to develop.
- Protein kinases are a group of enzymes that catalyze the phosphorylation of hydroxyl groups of certain protein residues, such as tyrosine, serine or threonine residues.
- one of the objects of the present invention is to provide a composition having anticancer activity, in particular in relation to kinases.
- Ras / Raf / MEK / ERK protein kinase signaling pathways play a very important role in the regulation of cell function and are specifically involved in cell proliferation, differentiation, survival and angiogenesis [Biology of the Cell, 2001, 93, 53-62].
- GTP guanosine triphosphate
- phosphorylation and activation of Raf protein in the plasma membrane proceed.
- Activated Raf protein then phosphorylates and activates MEK protein, which MEK phosphorylates and activates ERK protein.
- Translocation of the activated ERK from the cytoplasm to the nucleus results in the regulation and phosphorylation of the activity of transcription factors such as Elk-1 and Myc.
- the Raf protocogene is a serine / threon protein kinase that transfers signals from activated growth factor receptors to cell transcription factors in the nucleus.
- the activation of the Raf protein is accompanied by phosphorylation of tyrosine, serine, and threonine residues of the Raf protein, and direct phosphorylation by receptor tyrosine kinase or phosphorylation by protein kinase enzymes regulated by these receptors is a function of Raf activation. It is known by the mechanism. Of these, Ras is involved in the activation of Raf when regulated by the receptor.
- Raf The signal reaching Raf is delivered to the nucleus via a signaling pathway leading back to Raf / MEK / ERK protein kinase.
- a series of kinases are arranged in species to transmit signals, which play an essential role in cell growth and differentiation [Nature Rev. Mol. Cell. Biol., 2004, 5, 875 to 885]
- Raf acts as a major breeder of Ras function, providing a theoretical background for anticancer therapies for cancers that have mutated or activated Ras that inhibit the action of this protein.
- Raf proteins have three functional isoforms: A-raf, B-Raf, and C-Raf [Biochim. Biophys. Acta., 2003, 1653, 25-40], among which B-Raf plays an important role in linking MEK signaling in Ras. All three Raf genes are expressed in most tissues, with high expression of B-raf in neuronal tissues and A-raf in urogenital tissues.
- Each Raf family has a very similar amino acid sequence, but biochemical activity and biological function are distinguished from one another [Exp. Cell. Res.
- B-raf is an important isoform protein involved in cell proliferation and is an important target of tumorigenic Ras.
- Abnormal mutations in the body have been identified only in the case of B-raf, occur in 30-60% of malignant skin melanoma [Nature, 2002, 417, 949-954], 30-50% in thyroid cancer, colorectal cancer 5 20% and less than 30% of ovarian cancers [Nature Rev. Mol. Cell Biology, 2004, 5, 875-885.
- more than 45 B-raf mutations have been known, but the most frequent mutations have been observed in more than 90% of human cancers, with valine 600 being mutated to glutamic acid.
- This mutation increases B-raf's kinase activity and is believed to deliver Raf / MEK / ERK signals in a subsignal pathway that includes the structural activity of ERK as a result of Ras and growth factor receptor activation.
- Mutated B-raf protein is transformed in NIH3T3 cells [Nature, 2002, 417, 949-954] and melanocytes [Cancer Res., 2004, 64, 2338-2342] and also survives and transforms melanoma. It appears to be essential for [Cancer Res., 2003, 63, 5198 ⁇ 5202]. Therefore, B-raf, which plays a key role in the continuous signaling of Raf / MEK / ERK, plays an essential role in tumor survival.
- the present inventors conducted a long-term study to develop an inhibitor capable of modulating the activity of B-raf kinase, and thus synthesized a novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative of Formula 1
- the present invention since these derivatives exhibited excellent activity against Raf kinase, the present invention was found to have an excellent effect on diseases caused by Raf kinase overactivity.
- Another object of the present invention is to provide a method for preparing the furinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative or a pharmaceutically acceptable salt thereof.
- Another object of the present invention is to provide a method for preventing a disease caused by Raf kinase overactivity containing a purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative or a pharmaceutically acceptable salt thereof as an active ingredient or To provide a pharmaceutical composition for treatment.
- the present invention provides a furinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative represented by the following formula (1) or a pharmaceutically acceptable salt thereof.
- the present invention also provides a method for preparing the furinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative or a pharmaceutically acceptable salt thereof.
- the present invention provides a method for preventing or treating a disease caused by Raf kinase overactivity containing the purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative or a pharmaceutically acceptable salt thereof as an active ingredient. It provides a pharmaceutical composition.
- Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivatives according to the present invention effectively regulate the activity of B-raf kinase and are therefore diseases caused by overactivity of Raf kinase, especially cancer, melanoma, It can be usefully used for the prevention or treatment of colon cancer, prostate cancer, appreciable cancer, ovarian cancer.
- the present invention provides a novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative represented by the following formula (1) or a pharmaceutically acceptable salt thereof.
- R is C 1 -C 6 straight or branched alkyl; C 3 -C 6 cycloalkyl unsubstituted or substituted with one or more selected from the group consisting of halogen and C 1 -C 6 straight or branched alkyl; Halogen, with at least one member selected from the group consisting of straight or branched chain alkoxy of C 1 -C 6 straight or branched chain alkyl, C 1 -C 6 a C 1 -C 6 straight-chain or a branched chain alkoxy group and a halogen substituted in the substituted C 5 -C 6 aryl; Unsubstituted of C 1 -C 6 substituted by halogen, straight-chain or branched alkyl, a straight or branched chain alkyl-oxy-carbonyl, and the ring oxygen of the C 1 -C 6 straight or branched chain alkyl, C 1 -C 6 of (O) C 5 -C 12 single or bicyclic heteroary
- R is methyl; ethyl; profile; Isopropyl; Butyl; Isobutyl; Cyclopropyl; Cyclobutyl; Cyclopentyl; Cyclohexyl; Unsubstituted or chloro, fluoro, bromo, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, trifluoromethoxy, fluoromethoxy, difluoromethoxy And C 5 -C 6 aryl substituted with one or more selected from the group consisting of trifluoroethoxy; Unsubstituted or chloro, fluoro, bromo, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, methyloxycarbonyl, ethyloxycarbonyl, propyloxycarbonyl, butyloxycarbonyl, t-buty
- R is methyl; ethyl; profile; Isopropyl; Cyclopropyl; Cyclohexyl; Phenyl unsubstituted or substituted with one or more selected from the group consisting of chloro, fluoro, methyl, methoxy and trifluoromethoxy; Thiophene, thiazole, furan, imidazole, pyridine, dihydrobenzofuran, benzofuran, unsubstituted or substituted with at least one member selected from the group consisting of methyl, methyloxycarbonyl (methyl ester) and dioxolanyl, Chromman, benzothiazole, indole or pyrazole; Morpholine; Or phenylmethyl substituted with nitro.
- the purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivatives represented by Formula 1 of the present invention may be used in the form of a pharmaceutically acceptable salt, and the salt may be a pharmaceutically acceptable free acid ( Acid addition salts formed by free acid are useful.
- the expression pharmaceutically acceptable salt is a concentration that has a relatively nontoxic and harmless effect on the patient and that any side effects due to the salt do not degrade the beneficial efficacy of the base compound of formula 1, or Means inorganic addition salts.
- These salts may include inorganic acids and organic acids as free acids, hydrochloric acid, bromic acid, nitric acid, sulfuric acid, perchloric acid, phosphoric acid, and the like, and citric acid, acetic acid, lactic acid, maleic acid, and fumarine as organic acids.
- Acids Gluconic Acid, Methanesulfonic Acid, Glyconic Acid, Succinic Acid, Tartaric Acid, Galluturonic Acid, Embonic Acid, Glutamic Acid, Aspartic Acid, Oxalic Acid, (D) or (L) Malic Acid, Maleic Acid, Methanesulphonic Acid, Ethene Sulfuric Acid Phonic acid, 4-toluenesulfonic acid, salicylic acid, citric acid, benzoic acid or malonic acid and the like can be used.
- These salts also include alkali metal salts (sodium salts, potassium salts, and the like), alkaline earth metal salts (calcium salts, magnesium salts, and the like) and the like.
- acid addition salts include acetates, aspartates, benzates, besylates, bicarbonates / carbonates, bisulfates / sulfates, borates, camsylates, citrates, disylates, ecylates, formates, fumarates, Gluceptate, Gluconate, Glucuronate, Hexafluorophosphate, Hibenzate, Hydrochloride / Chloride, Hydrobromide / Bromide, Hydroiodide / Iodide, Isetionate, Lactate, Maleate, Mali Eate, malonate, mesylate, methylsulfate, naphthylate, 2-naphsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate / hydrogen phosphate / dihydrogen phosphate, saccha Laterate, stearate, succinate, tartrate, tosy
- purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative represented by Chemical Formula 1 of the present invention is not only a pharmaceutically acceptable salt, but also all salts that can be prepared by a conventional method, Include all isomers, hydrates, and solvates.
- the addition salt according to the present invention can be prepared by a conventional method, for example, by dissolving the compound of Formula 1 in a water miscible organic solvent such as acetone, methanol, ethanol, or acetonitrile and adding an excess of an organic acid or an inorganic acid. It can be prepared by adding an aqueous acid solution of, followed by precipitation or crystallization. The solvent or excess acid may then be evaporated and dried in this mixture to obtain an addition salt or the precipitated salt may be prepared by suction filtration.
- a water miscible organic solvent such as acetone, methanol, ethanol, or acetonitrile
- a process for preparing the purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative of claim 1 comprising the step of reacting a compound of formula 2 with a compound of formula 3 under a base and a solvent to obtain a compound of formula 1 to provide.
- R is as defined in Formula 1).
- the base is lithium (bistrimethylsilyl) amide and the solvent may be tetrahydrofuran.
- the compound of Formula 2 and the compound of Formula 3 are dissolved in tetrahydrofuran as a solvent, and then slowly added to a base lithium (bistrimethylsilyl) amide at 0 ° C. and stirred at room temperature for 1 hour to purify the compound of Formula 1 Nylpyridinylamino-2,4-difluorophenyl sulfonamide derivatives can be prepared.
- Preparation of the purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative of claim 1 comprising the step of reacting a compound of formula 4 with a sulfonyl compound of formula 5 under a base and a solvent to obtain a compound of formula 1 Provide a method.
- R is as defined in Formula 1).
- the base is pyridine and the solvent may be dichloromethane.
- the compound of Formula 4 may be prepared by adding the compound of Formula 4, the sulfonyl compound of Formula 5, and pyridine, which is a base, to a solvent, and stirred at 50 ° C. for 2 hours.
- the present invention is caused by the overactivity of Raf kinase containing a purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative represented by the formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient It provides a pharmaceutical composition for the prevention or treatment of disease.
- Diseases caused by Raf kinase overactivity may include cancer, in particular, melanoma, colorectal cancer, prostate cancer, auditory cancer, and ovarian cancer.
- Raf proteins have three isoforms, A-raf, B-Raf, and C-Raf (Biochim. Biophys. Acta., 2003, 1653, 25-40), among which B-Raf Plays an important role in connecting MEK signaling in Ras. So far, B-raf is an important isoform that is involved in cell proliferation and is an important target for tumorigenic Ras. Abnormal mutations in the body have only been identified in B-raf cases. It occurs at a frequency of ⁇ 60% (Nature, 2002, 417, 949 ⁇ 954), and is reported to occur in 30% to 50% of thyroid cancer, 5% to 20% of colorectal cancer, and less than 30% in ovarian cancer. (Nature Rev. Mol.
- mutated B-raf proteins are NIH3T3 cells (Nature, 2002, 417, 949-954) and black cells (Cancer Res., 2004, 64). , 2338-2342), and is also essential for the survival and transformation of melanoma (Cancer Res., 2003, 63, 5198-5202).
- the mutation is believed to increase the kinase activity of B-raf and deliver Raf / MEK / ERK signals in a subsignal pathway that includes the structural activity of ERK as a result of Ras and growth factor receptor activation.
- B-raf kinase activity and B-raf cell activity of the purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative represented by Formula 1 according to the present invention were measured. It showed excellent inhibitory activity against raf kinase (see Experimental Example 1). In addition, in vitro experiments showed excellent inhibitory activity against B-raf cell activity (see Experimental Example 2).
- the purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivatives according to the present invention exhibit excellent inhibitory activity against B-raf kinase and B-raf cell activity that cause Raf kinase overactivity. It can be usefully used for the prevention or treatment of diseases caused by kinase overactivity.
- composition of the present invention a pharmaceutical composition containing the purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient
- the composition may be formulated and administered in various oral or parenteral dosage forms as described below, but is not limited thereto.
- Formulations for oral administration include, for example, tablets, pills, hard / soft capsules, solutions, suspensions, emulsifiers, syrups, granules, elixirs, and the like.
- Rose sucrose, mannitol, sorbitol, cellulose and / or glycine
- lubricants such as silica, talc, stearic acid and its magnesium or calcium salts and / or polyethylene glycols.
- Tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidine, and optionally such as starch, agar, alginic acid or its sodium salt.
- Disintegrant or boiling mixtures and / or absorbents, colorants, flavors, and sweeteners include, for example, tablets, pills, hard / soft capsules, solutions, suspensions, emulsifiers, syrups, granules, elixir
- the pharmaceutical composition comprising the derivative represented by Formula 1 as an active ingredient may be administered parenterally, and the parenteral administration may be by injection of subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection.
- the purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative of Formula 1 or a pharmaceutically acceptable salt thereof is mixed with water together with a stabilizer or a buffer. It may be prepared in solution or in suspension and prepared in ampoules or vial unit dosage forms.
- the compositions may contain sterile and / or preservatives, stabilizers, hydrating or emulsifying accelerators, auxiliaries such as salts and / or buffers for the control of osmotic pressure, and other therapeutically useful substances, and conventional methods of mixing, granulating It may be formulated according to the formulation or coating method.
- the dosage of the compound of the present invention to the human body may vary depending on the age, weight, sex, dosage form, health condition and degree of disease of the patient, and generally based on an adult patient having a weight of 70 kg. It is 0.1-1,000 mg / day, Preferably it is 1-500 mg / day, It can also divide and administer once a day to several times at regular time intervals according to a decision of a doctor or a pharmacist.
- Diseases caused by Raf kinase overactivity may include cancer, in particular, melanoma, colorectal cancer, prostate cancer, auditory cancer, and ovarian cancer.
- composition according to the present invention by acting as an inhibitor of Raf kinase overactivity, the purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative for the purpose of preventing or ameliorating diseases caused by Raf kinase overactivity. It can be added to dietary supplements such as beverages.
- Examples of foods to which the above-mentioned substances may be added include dairy products, various soups, drinks, meat, sausages, breads, biscuits, rice cakes, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, Beverages, alcoholic beverages and vitamin complexes, dairy products and dairy products, and the like includes all the health functional foods in the conventional sense.
- the phthalazinone derivatives of the present invention may be added as is to foods or used with other foods or food ingredients, and may be suitably used according to conventional methods.
- the mixing amount of the active ingredient can be suitably determined according to the purpose of use (prevention or improvement).
- the amount of the compound in the health food can be added at 0.1 to 90 parts by weight of the total food weight.
- the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.
- the health functional beverage composition of the present invention is not particularly limited to other ingredients except for containing the compound as an essential ingredient in the indicated ratios, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks.
- natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
- natural flavoring agents such as, tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used.
- the proportion of natural carbohydrates is generally from about 1 to 20 g, preferably from about 5 to 12 g per 100 compositions of the present invention.
- phthalazinone derivatives of the present invention include various nutrients, vitamins, minerals (electrolytes), synthetic flavoring agents such as natural and natural flavoring agents, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, Alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks and the like.
- the phthalazinone derivatives of the present invention may contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages.
- phthalazinone derivative of the invention is in the range of 0.1 to about 20 parts by weight per 100 parts by weight.
- the present invention provides a Raf kinase comprising the step of administering a purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative represented by the formula (1) or a pharmaceutically acceptable salt thereof to a patient in need thereof It provides a method for the prevention or treatment of diseases caused by overactivity of.
- the present invention provides a purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative represented by Formula 1 used in the prevention or treatment of a disease caused by the overactivity of Raf kinase, or a pharmaceutically thereof.
- 2,6-Difluoro-3-nitrobenzoic acid (16 g, 79 mmol) prepared in Step 1 was added to a mixed solvent of dichloromethane and N, N-dimethylformamide, and oxalyl chloride (14 mL, 158 mmol) was added. Was added slowly. The reaction was stirred at room temperature for 18 hours, the solvent was concentrated and the residue was diluted with dichloromethane and N, N-dimethylformamid and the temperature was lowered to 0 ° C. Sodium azide (5.6 g, 87 mmol) was slowly added little by little. After stirring 30 minutes at room temperature tert-butanol (40 mL) was added.
- Step 3 Preparation of tert-butyl-3-amino-2,6-difluorophenylcarbamate
- Step 4 Preparation of tert-butyl-2,6-difluoro-3- (1-methylethylsulfonamido) phenylcarbamate
- the tert-butyl-3-amino-2,6-difluorophenylcarbamate (100 mg, 0.41 mmol) prepared in step 3 was added to the dichloromethane solvent and dissolved.
- 2-propanesulfonyl chloride (50 uL, 0.45 mmol) and pyridine (36 uL, 0.045 mmol) were added to the reaction solution, and the mixture was stirred at 50 ° C. for 2 hours. After the reaction was completed, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- 6-Chloro-9H-purine 500 mg, 3.2 mmol
- 4-methylbenzenesulfonyl acid 12 mg, 0.07 mmol
- 3,4-dihydro-2H-pyran 0.9 mL, 9.7 mmol
- the reaction was stirred at 90 ° C. for about 1 hour until the solid dissolved.
- the solvent was concentrated and the residue was purified by column chromatography to give 749 mg (yield: 97%) of the target product 6-chloro-9- (tetrahydro-2H-pyran-2-yl) -9H-purine.
- Step 7 Preparation of 6- (2-fluoropyridin-3-yl) -9- (tetrahydro-2H-pyran-2-yl) -9H-purine
- Step 8 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) propane-2-sulfonamide
- Step 9 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) propane-2-sulfonamide
- Step 4 Preparation of benzyl tertiarybutyl (2,4-difluoro-1,3-phenylene) dicarbamate
- Benzyl tert-butyl (2,4-difluoro-1,3-phenylene) dicarbamate 400 mg, 1.06 mmol
- ethyl acetate solvent 4M hydrogen chloride solution (1.3) was added.
- mL, 4M in 1,4-dioxane was added and stirred at room temperature for 5 hours.
- the solvent was concentrated and the solid filtered under reduced pressure was washed with diethyl ether to obtain 276 mg (yield: 94%) of the target product, benzyl 3-amino-2,4-difluorophenylcarbamate.
- Step 6 and Step 7 Preparation of 6- (2-fluoropyridin-3-yl) -9- (tetrahydro-2H-pyran-2-yl) -9H-purine
- Step 8 benzyl-2,4-difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) phenyl
- Benzyl 3-amino-2,4-difluorophenylcarbamate (100 mg, 0.32 mmol) prepared in step 5 above with anhydrous tetrahydrofuran and 6- (2-fluoropyridine-3 prepared in step 7 above -Yl) -9- (tetrahydro-2H-pyran-2-yl) -9H-purine (86 mg, 0.29 mmol) was added to dissolve and lithium (bistrimethylsilyl) amide (1.0 M solution in THF, 1.45 mL) was added slowly. The reaction was stirred for 1 hour and after the reaction was completed, water was added and extracted with ethyl acetate.
- Benzyl-2,4-difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine- prepared in step 8 in a methanol solvent.
- 2-ylamino) phenyl carbamate 100 mg, 0.18 mmol was dissolved, palladium / carbon (50 mg) was added thereto, and the mixture was stirred for 1 hour under hydrogen pressure.
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) -3- (trifluoromethyl) benzenesulfonamide
- 2,6-Difluoro-N-1- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine prepared in step 9 above in dichloromethane solvent 2-yl) benzene-1,3-diamine (20 mg, 0.047 mmol), 3- (trifluoromethyl) benzenesulfonyl chloride (8 uL, 0.052 mmol) and pyridine (8 uL, 0.094 mmol) Stir at 50 ° C. for 2 hours. After completion of the reaction, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- Step 11 of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -3- (trifluoromethyl) benzenesulfonamide Produce
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) -4- (trifluoromethyl) benzenesulfonamide
- 2,6-Difluoro-N-1- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine prepared in step 9 above in dichloromethane solvent 2-yl) benzene-1,3-diamine (20 mg, 0.047 mmol), 4- (trifluoromethyl) benzenesulfonyl chloride (13 mg, 0.052 mmol) and pyridine (8 uL, 0.094 mmol) Stir at 50 ° C. for 2 hours. After the reaction was completed, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- Step 11 of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -4- (trifluoromethyl) benzenesulfonamide Produce
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) thiophen-2-sulfonamide
- 2,6-Difluoro-N-1- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine prepared in step 9 above in dichloromethane solvent 2-yl) benzene-1,3-diamine (20 mg, 0.047 mmol), 3-thiophensulfonyl chloride (13 mg, 0.052 mmol) and pyridine (8 uL, 0.094 mmol) were added and the mixture was heated at 50 ° C. for 2 hours. Was stirred. After the reaction was completed, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) thiophen-2-sulfonamide
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) propane-1-sulfonamide
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) propane-1-sulfonamide
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -3,4-dichlorobenzenesulfonamide
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamine) Preparation of Phenyl) benzofuran-2-sulfonamide
- 2,6-difluoro-N1- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine-2 prepared in step 9 above in dichloromethane solvent -Yl) benzene-1,3-diamine (20 mg, 0.047 mmol), 2-benzofuransulfonyl chloride (15 mg, 0.052 mmol) and pyridine (8 uL, 0.094 mmol) were added and stirred at 50 ° C. for 2 hours. It was. After the reaction was completed, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) benzofuran-2-sulfonamide
- Step 10 4-Chloro-N- (2,4-difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine-2 Preparation of -ylamino) phenyl) -2-fluorobenzenesulfonamide
- 2,6-difluoro-N1- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine-2 prepared in step 9 above in dichloromethane solvent -Yl) benzene-1,3-diamine (20 mg, 0.047 mmol), 4-chloro-2-fluorobenzenesulfonyl chloride (16 mg, 0.052 mmol) and pyridine (8 uL, 0.094 mmol) were added and 50 ° C. Stirred for 2 h. After the reaction was completed, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- Step 11 of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -4-chloro-2-fluorobenzenesulfonamide Produce
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) -1- (2-nitrophenyl) methanesulfonamide
- 2,6-Difluoro-N-1- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine prepared in step 9 above in dichloromethane solvent 2-yl) benzene-1,3-diamine (20 mg, 0.047 mmol), (2-nitrophenyl) methanesulfonyl chloride (12 mg, 0.052 mmol) and pyridine (8 uL, 0.094 mmol) were added and 50 ° C. Stirred for 2 h. After the reaction was completed, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- Step 11 of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -1- (2-nitrophenyl) methanesulfonamide Produce
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) -3,4-dimethoxybenzenesulfonamide
- 2,6-difluoro-N1- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine-2 prepared in step 9 above in dichloromethane solvent -Yl) benzene-1,3-diamine (20 mg, 0.047 mmol), 3,4-dimethoxybenzenesulfonyl chloride (12 mg, 0.052 mmol) and pyridine (8 uL, 0.094 mmol) were added at 50 ° C. Stir for hours. After the reaction was completed, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -3,4-dimethoxybenzenesulfonamide
- 2,6-difluoro-N1- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine-2 prepared in step 9 above in dichloromethane solvent -Yl) benzene-1,3-diamine (20 mg, 0.047 mmol), cyclohexanesulfonyl chloride (10 mg, 0.052 mmol) and pyridine (8 uL, 0.094 mmol) were added and stirred at 50 ° C. for 2 hours. After the reaction was completed, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) cyclohexanesulfonamide
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) -4- (trifluoromethoxy) benzenesulfonamide
- 2,6-difluoro-N1- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine-2 prepared in step 9 above in dichloromethane solvent -Yl) benzene-1,3-diamine (20 mg, 0.047 mmol), 4- (trifluoromethoxy) benzenesulfonyl chloride (18 mg, 0.07 mmol) and pyridine (8 uL, 0.094 mmol) were added and 50 ° C. Stirred for 2 h. After the reaction was completed, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- Step 11 of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -4- (trifluoromethoxy) benzenesulfonamide Produce
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) -4-fluoro-2- (trifluoromethyl) benzenesulfonamide
- 2,6-difluoro-N1- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine-2 prepared in step 9 above in dichloromethane solvent -Yl) benzene-1,3-diamine (20 mg, 0.047 mmol), 4-fluoro-2- (trifluoromethyl) benzenesulfonyl chloride (18 mg, 0.07 mmol) and pyridine (8 uL, 0.094 mmol ) was added and stirred at 50 ° C. for 2 hours. After the reaction was completed, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- Step 11 N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -4-fluoro-2- (trifluoromethyl Preparation of Benzenesulfonamide
- Step 10 3-Chloro-N- (2,4-difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine-2 Preparation of -ylamino) phenyl) -2-methylbenzenesulfonamide
- 2,6-difluoro-N1- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine-2 prepared in step 9 above in dichloromethane solvent -Yl) benzene-1,3-diamine (20 mg, 0.047 mmol), 3-chloro-2-methylbenzene-1-sulfonyl chloride (16 mg, 0.07 mmol) and pyridine (8 uL, 0.094 mmol) were added thereto. Stir at 50 ° C. for 2 hours. After the reaction was completed, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -3-chloro-2-methylbenzenesulfonamide
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) furan-2-sulfonamide
- 2,6-difluoro-N1- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine-2 prepared in step 10 above in dichloromethane solvent -Yl) benzene-1,3-diamine (20 mg, 0.047 mmol), furan-2-sulfonyl chloride (12 mg, 0.07 mmol) and pyridine (8 uL, 0.094 mmol) were added and stirred at 50 ° C. for 2 hours. It was. After the reaction was completed, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) furan-2-sulfonamide
- Step 10 Methyl-3- (N- (2,4-difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine- Preparation of 2-ylamino) phenyl) sulfamoyl) thiophen-2-carboxylate
- Step 11 methyl-3- (N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) sulfamoyl) thiophen-2- Preparation of Capboxylate
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) thiophen-3-sulfonamide
- 2,6-difluoro-N1- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine-2 prepared in step 9 above in dichloromethane solvent -Yl) benzene-1,3-diamine (20 mg, 0.047 mmol), thiophen-3-sulfonyl chloride (13 mg, 0.07 mmol) and pyridine (8 uL, 0.094 mmol) were added at 50 ° C. for 2 hours. Stirred. After the reaction was completed, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) thiophen-3-sulfonamide
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) furan-3-sulfonamide
- 2,6-difluoro-N-1- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine prepared in step 10 above in dichloromethane solvent -2-yl) benzene-1,3-diamine (20 mg, 0.047 mmol), furan-3-sulfonyl chloride (12 mg, 0.07 mmol) and pyridine (8 uL, 0.094 mmol) were added thereto at 50 ° C. for 2 hours. Was stirred. After the reaction was completed, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) furan-3-sulfonamide
- 2,6-difluoro-N1- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine-2 prepared in step 9 above in dichloromethane solvent -Yl) benzene-1,3-diamine (20 mg, 0.047 mmol), cyclopropanesulfonyl chloride (10 mg, 0.052 mmol) and pyridine (8 uL, 0.094 mmol) were added and stirred at 50 ° C. for 2 hours. After the reaction was completed, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) cyclopropanesulfonamide
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) -2,4-dimethylthiazole-5-sulfonamide
- Step 11 N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -2,4-dimethylthiazol-5-sulfonamide
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) morpholin-4-sulfonamide
- 2,6-Difluoro-N-1- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine prepared in step 9 above in dichloromethane solvent -2-yl) benzene-1,3-diamine (50 mg, 0.120 mmol), morpholin-4-sulfonyl chloride (24 mg, 0.130 mmol) and pyridine (11 uL, 0.130 mmol) were added at 50 ° C. Stir for hours. After the reaction was completed, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) morpholin-4-sulfonamide
- Example 1 tertiary-butyl-3-amino-2,6-difluorophenylcarbamate was prepared in the same manner as in steps 1 to 3.
- Step 4 Preparation of tert-butyl-2,6-difluoro-3- (1-methyl-1H-imidazole-4-sulfonamido) phenylcarbamate
- the tert-butyl-3-amino-2,6-difluorophenylcarbamate (50 mg, 0.20 mmol) prepared in step 3 was added and dissolved in a dichloromethane solvent.
- 1-methyl-1H-imidazole-4-sulfonyl chloride (44 uL, 0.25 mmol) and pyridine (50 uL, 0.61 mmol) were added to the reaction solution, and the mixture was stirred at 50 ° C. for 2 hours. After the reaction was completed, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- Step 5 Preparation of N- (3-amino-2,4-difluorophenyl) -1-methyl-1H-imidazole-4-sulfonamide
- Step 6 and Step 7 Preparation of 6- (2-fluoropyridin-3-yl) -9- (tetrahydro-2H-pyran-2-yl) -9H-purine
- Step 8 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) -1-methyl-1H-imidazole-4-sulfonamide
- N- (3-amino-2,4-difluorophenyl) -1-methyl-1H-imidazole-4-sulfonamide (45 mg, 0.16 mmol) prepared in step 5 and prepared in step 7 6- (2-fluoropyridin-3-yl) -9- (tetrahydro-2H-pyran-2-yl) -9H-purine (43 mg, 0.14 mmol) was added and dissolved, followed by lithium (bistrimethyl) at 0 ° C. Silyl) amide (1.0 M solution in THF) was added slowly. The reaction was stirred at room temperature for 1 hour and after the reaction was completed, water was added and extracted with ethyl acetate.
- Step 9 N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -1-methyl-1H-imidazole-4-sulphone Preparation of Amides
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) -5-methylfuran-2-sulfonamide
- 2,6-Difluoro-N-1- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine prepared in step 9 above in dichloromethane solvent -2-yl) benzene-1,3-diamine (50 mg, 0.120 mmol), 5-methylfuran-2-sulfonyl chloride (24 mg, 0.130 mmol) and pyridine (11 uL, 0.130 mmol) were added and 50 ° C. Stirred for 1 h. After the reaction was completed, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -5-methylfuran-2-sulfonamide
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) -5- (1,3-dioxolan-2-yl) furan-2-sulfonamide
- 2,6-difluoro-N1- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine-2 prepared in step 9 above in dichloromethane solvent -Yl) benzene-1,3-diamine (50 mg, 0.120 mmol), 5- (1,3-dioxolan-2-yl) furan-2-sulfonyl chloride (24 mg, 0.130 mmol) and pyridine (11 uL, 0.130 mmol) was added and stirred at 50 ° C. for 1 hour. After the reaction was completed, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- Step 11 N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -5- (1,3-dioxolane-2- (1) Preparation of furan-2-sulfonamide
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) -2,5-dimethylfuran-3-sulfonamide
- 2,6-difluoro-N1- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine-2 prepared in step 9 above in dichloromethane solvent -Yl) benzene-1,3-diamine (50 mg, 0.120 mmol), 2,5-dimethylfuran-3-sulfonyl chloride (24 mg, 0.130 mmol) and pyridine (11 uL, 0.130 mmol) were added and 50 Stir at 1 ° C. for 1 h. After the reaction was completed, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- Step 11 N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -2,5-dimethylfuran-3-sulfonamide
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) -5-methyl-2- (trifluoromethyl) furan-3-sulfonamide
- 2,6-difluoro-N1- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine-2 prepared in step 9 above in dichloromethane solvent -Yl) benzene-1,3-diamine (50 mg, 0.120 mmol), 5-methyl-2- (trifluoromethyl) furan-3-sulfonyl chloride (24 mg, 0.130 mmol) and pyridine (11 uL, 0.130 mmol) was added and stirred at 50 ° C. for 1 hour. After the reaction was completed, the reaction was washed with 1N aqueous hydrochloric acid solution and brine and extracted with dichloromethane.
- Step 10 2-Chloro-N- (2,4-difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine-2 Preparation of -ylamino) phenyl) -6-methylbenzenesulfonamide
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -2-chloro-6-methylbenzenesulfonamide
- Step 10 3-Chloro-N- (2,4-difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine-2 Preparation of -ylamino) phenyl) -4-fluorobenzenesulfonamide
- Step 11 of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -3-chloro-4-fluorobenzenesulfonamide Produce
- Step 10 3-Chloro-N- (2,4-difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine-2 Preparation of -ylamino) phenyl) -2-fluorobenzenesulfonamide
- Step 11 of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -3-chloro-4-fluorobenzenesulfonamide Produce
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) pyridine-3-sulfonamide
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) pyridine-3-sulfonamide
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) -2-methylbenzenesulfonamide
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -2-methylbenzenesulfonamide
- Step 10 2-Chloro-N- (2,4-difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine-2 Preparation of -ylamino) phenyl) benzenesulfonamide
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -2-chlorobenzenesulfonamide
- Step 10 3-Chloro-N- (2,4-difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine-2 Preparation of -ylamino) phenyl) benzenesulfonamide
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -3-chlorobenzenesulfonamide
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -2,3-chlorobenzenesulfonamide
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) benzenesulfonamide
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) benzenesulfonamide
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) -2,3-dihydrobenzofuran-7-sulfonamide
- Step 11 N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -2,3-dihydrobenzofuran-7-sulfone Preparation of Amides
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) benzofuran-7-sulfonamide
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) benzofuran-7-sulfonamide
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) chroman-8-sulfonamide
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) chroman-8-sulfonamide
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) -2-methylbenzo [d] thiazole-6-sulfonamide
- Step 11 N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -2-methylbenzo [d] thiazole-6- Preparation of Sulfonamide
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) -1-methyl-1H-indole-5-sulfonamide
- Step 11 N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -1-methyl-1H-indole-5-sulfonamide
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) -1-methyl-1H-indole-4-sulfonamide
- Step 11 N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -1-methyl-1H-indol-4-sulfonamide
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) -1-methyl-1H-indole-7-sulfonamide
- Step 11 N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -1-methyl-1H-indole-7-sulfonamide
- Step 10 N- (2,4-Difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridin-2-ylamino) Preparation of Phenyl) -1-methyl-1H-pyrazole-4-sulfonamide
- Step 11 N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -1-methyl-1H-pyrazole-4-sulphone Preparation of Amides
- Step 10 5-Chloro-N- (2,4-difluoro-3- (3- (9- (tetrahydro-2H-pyran-2-yl) -9H-purin-6-yl) pyridine-2 Preparation of -ylamino) phenyl) thiophen-2-sulfonamide
- Step 11 Preparation of N- (3- (3- (9H-purin-6-yl) pyridin-2-ylamino) -2,4-difluorophenyl) -5-chlorothiophen-2-sulfonamide
- Example Compound B-raf enzyme activity IC 50 ( ⁇ M)
- Example 1 0.017
- Example 2 0.0088
- Example 3 0.030
- Example 4 0.012
- Example 5 0.023
- Example 6 0.72
- Example 7 0.832
- Example 8 0.0337
- Example 9 1.5
- Example 10 1.2
- Example 11 0.206
- Example 12 0.610
- Example 13 0.42
- Example 14 0.002
- Example 15 0.001
- Example 16 1.5
- Example 17 0.007 Example 18 0.001
- Example 19 0.05
- Example 20 0.16
- Example 21 1.3
- Example 22 1.8
- Example 23 0.015
- Example 24 0.22
- Example 25 0.015
- Example 26 0.03
- Example 27 0.08
- Example 28 0.3
- Example 29 0.08
- Example 30 0.004
- Example 31 0.05
- Example 32 0.03
- Example 33 0.08
- Example 34 0.04
- Example 35 0.02
- Example 36 1.02
- Example 37 0.09
- Example 38
- the compound according to the present invention exhibited an excellent inhibitory effect on B-raf activity of 0.001 ⁇ 1.8 ⁇ M of B-raf activity, the B-raf activity inhibition rate of most compounds is less than 1 ⁇ M excellent B- It can be seen that the raf inhibitory activity.
- the A375P cell line (ATCC) is derived from human melanoma patients and has a V600E mutation of the B-Raf gene.
- A375 cells were maintained in DMEM supplemented with 10% fetal bovine serum, glutamine (2 mM), penicillin (100 U / mL) and streptomycin (100 ⁇ g / mL). The cells were maintained at 37 ° C., 5% CO 2 and 100% humidity. For growth inhibition experiments, cells were plated at 1000 cells / 20 ⁇ l per well in white 384 well microplates.
- Example 10 Example 11 0.34 Example 12 0.6 Example 13 0.15 Example 14 0.006 Example 15 11.0 Example 16 9.6 Example 17 0.04 Example 18 0.002 Example 19 0.25 Example 20 0.7 Example 21 0.36 Example 22 1.0 Example 23 0.06 Example 24 0.8 Example 25 0.1 Example 26 0.33 Example 27 0.76 Example 28 1.93 Example 29 0.72 Example 30 0.07 Example 31 0.67 Example 32 0.44 Example 33 0.77 Example 34 0.5 Example 35 0.16 Example 36 8.37 Example 37 0.81 Example 38 7.19 Example 39 2.93 Example 40 > 15 Example 41 4.20 Example 42 5.87 Example 43 1.37 Example 44 0.2
- the compounds according to the present invention showed excellent activity inhibition rate of 0.006 ⁇ 11.2 ⁇ M activity of A375P cells, it was confirmed that most compounds show excellent anticancer inhibitory activity as the activity inhibition rate is less than 1 ⁇ M Can be.
- the compounds shown in the examples of the present invention are useful as therapeutic agents for abnormal diseases such as B-raf activity, such as cancer, in particular, melanoma, colorectal cancer, kidney cancer, prostate cancer, appreciative cancer and ovarian cancer. Can be used.
- abnormal diseases such as B-raf activity, such as cancer, in particular, melanoma, colorectal cancer, kidney cancer, prostate cancer, appreciative cancer and ovarian cancer.
- cancer in particular, melanoma, colorectal cancer, kidney cancer, prostate cancer, appreciative cancer and ovarian cancer.
- purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative represented by Formula 1 according to the present invention can be formulated in various forms according to the purpose.
- the following are some examples of formulation methods containing the compound represented by Formula 1 according to the present invention as an active ingredient, but the present invention is not limited thereto.
- tablets were prepared by tableting according to a conventional method for producing tablets.
- the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.
- an injection was prepared by containing the above components in the contents shown.
- Vitamin B6 0.5 mg
- composition ratio of the vitamin and mineral mixture is a composition suitable for a relatively healthy food in a preferred embodiment
- the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method.
- the granules may be prepared and used for preparing a health food composition according to a conventional method.
- the resulting solution is filtered and obtained in a sterilized 2 l container, sealed and sterilized and then refrigerated and then stored in a healthy beverage composition Used for preparation.
- composition ratio is a composition that is relatively suitable for a preferred beverage in a preferred embodiment
- the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.
- drinks were prepared using conventional methods.
- Chewing gum was prepared using conventional methods using the above composition and content.
- furinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative of Formula 1 is added to 100 parts by weight of wheat flour, and the mixture is used to prepare bread, cake, cookies, crackers and noodles. To produce a health promoting food.
- furinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative of Formula 1 was added to 100 parts by weight of milk, and various dairy products such as butter and ice cream were prepared using the milk.
- Brown rice, barley, glutinous rice, and yulmu were alphanated by a known method to distribute the dried ones, and then prepared into a powder having a particle size of 60 mesh.
- Black soybeans, black sesame seeds, and perilla were also steamed and dried in a known manner to prepare a powder having a particle size of 60 mesh using a grinder.
- the grains and seeds prepared above and the purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative of the formula (1) of the present invention were prepared by combining the following ratios.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
화학식 | 구 조 | 화학식 | 구 조 |
1 | 2 | ||
3 | 4 | ||
5 | 6 | ||
7 | 8 | ||
9 | 10 | ||
11 | 12 | ||
13 | 14 | ||
15 | 16 | ||
17 | 18 | ||
19 | 20 | ||
21 | 22 | ||
23 | 24 | ||
25 | 26 | ||
27 | 28 | ||
29 | 30 | ||
31 | 32 | ||
33 | 34 | ||
35 | 36 | ||
37 | 38 | ||
39 | 40 | ||
41 | 42 | ||
43 | 44 |
실시예 화합물 | B-raf 효소활성; IC50(μM) |
실시예 1 | 0.017 |
실시예 2 | 0.0088 |
실시예 3 | 0.030 |
실시예 4 | 0.012 |
실시예 5 | 0.023 |
실시예 6 | 0.72 |
실시예 7 | 0.832 |
실시예 8 | 0.0337 |
실시예 9 | 1.5 |
실시예 10 | 1.2 |
실시예 11 | 0.206 |
실시예 12 | 0.610 |
실시예 13 | 0.42 |
실시예 14 | 0.002 |
실시예 15 | 0.001 |
실시예 16 | 1.5 |
실시예 17 | 0.007 |
실시예 18 | 0.001 |
실시예 19 | 0.05 |
실시예 20 | 0.16 |
실시예 21 | 1.3 |
실시예 22 | 1.8 |
실시예 23 | 0.015 |
실시예 24 | 0.22 |
실시예 25 | 0.015 |
실시예 26 | 0.03 |
실시예 27 | 0.08 |
실시예 28 | 0.3 |
실시예 29 | 0.08 |
실시예 30 | 0.004 |
실시예 31 | 0.05 |
실시예 32 | 0.03 |
실시예 33 | 0.08 |
실시예 34 | 0.04 |
실시예 35 | 0.02 |
실시예 36 | 1.02 |
실시예 37 | 0.09 |
실시예 38 | 0.9 |
실시예 39 | 0.4 |
실시예 40 | >10 |
실시예 41 | 0.55 |
실시예 42 | 0.8 |
실시예 43 | 0.12 |
실시예 44 | 0.02 |
실시예 화합물 | 세포활성(A375P), IC50 (μM) |
실시예 1 | 0.12 |
실시예 2 | 0.23 |
실시예 3 | 5.2 |
실시예 4 | 0.03 |
실시예 5 | 0.31 |
실시예 6 | 2.8 |
실시예 7 | 4.3 |
실시예 8 | 0.7 |
실시예 9 | 11.2 |
실시예 10 | 10.2 |
실시예 11 | 0.34 |
실시예 12 | 0.6 |
실시예 13 | 0.15 |
실시예 14 | 0.006 |
실시예 15 | 11.0 |
실시예 16 | 9.6 |
실시예 17 | 0.04 |
실시예 18 | 0.002 |
실시예 19 | 0.25 |
실시예 20 | 0.7 |
실시예 21 | 0.36 |
실시예 22 | 1.0 |
실시예 23 | 0.06 |
실시예 24 | 0.8 |
실시예 25 | 0.1 |
실시예 26 | 0.33 |
실시예 27 | 0.76 |
실시예 28 | 1.93 |
실시예 29 | 0.72 |
실시예 30 | 0.07 |
실시예 31 | 0.67 |
실시예 32 | 0.44 |
실시예 33 | 0.77 |
실시예 34 | 0.5 |
실시예 35 | 0.16 |
실시예 36 | 8.37 |
실시예 37 | 0.81 |
실시예 38 | 7.19 |
실시예 39 | 2.93 |
실시예 40 | >15 |
실시예 41 | 4.20 |
실시예 42 | 5.87 |
실시예 43 | 1.37 |
실시예 44 | 0.2 |
Claims (16)
- 하기 화학식 1로 표시되는 신규한 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체 또는 이의 약학적으로 허용가능한 염:[화학식 1](상기 화학식 1에서,R은 C1-C6의 직쇄 또는 측쇄 알킬; 비치환되거나 할로겐 및 C1-C6의 직쇄 또는 측쇄 알킬로 이루어지는 군으로부터 선택되는 1종 이상으로 치환된 C3-C6 시클로알킬; 할로겐, C1-C6의 직쇄 또는 측쇄 알킬, C1-C6의 직쇄 또는 측쇄 알콕시 및 할로겐으로 치환된 C1-C6의 직쇄 또는 측쇄 알콕시로 이루어지는 군으로부터 선택되는 1종 이상으로 치환된 C5-C6 아릴; 비치환되거나 할로겐으로 치환된 C1-C6의 직쇄 또는 측쇄 알킬, C1-C6의 직쇄 또는 측쇄 알킬, C1-C6의 직쇄 또는 측쇄 알킬옥시카보닐 및 고리 내 산소(O)를 1 이상 포함하는 C5-C6 헤테로시클로알킬로 이루어지는 군으로부터 선택되는 1종 이상으로 치환된 C5-C12 단일 또는 이중고리의 헤테로아릴; 비치환되거나 할로겐 및 C1-C6의 직쇄 또는 측쇄 알킬로 이루어지는 군으로부터 선택되는 1종 이상으로 치환된 C5-C6 헤테로시클로알킬; 또는 비치환되거나 할로겐, 니트로 및 C1-C6의 직쇄 또는 측쇄 알킬로 치환된 C5-C6 아릴 C1-C6의 직쇄 또는 측쇄 알킬이고, 여기서, 상기 헤테로아릴 및 헤테로시클로알킬은 고리 내 N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 포함한다).
- 제1항에 있어서,상기 R은 메틸; 에틸; 프로필; 이소프로필; 부틸; 이소부틸; 시클로프로필; 시클로부틸; 시클로펜틸; 시클로헥실; 비치환되거나 클로로, 플루오로, 브로모, 메틸, 에틸, 프로필, 이소프로필, 부틸, 이소부틸, 메톡시, 에톡시, 프로폭시, 부톡시, 트리플루오로메톡시, 플루오로메톡시, 디플루오로메톡시 및 트리플루오로에톡시로 이루어지는 군으로부터 선택되는 1종 이상으로 치환된 C5-C6 아릴; 비치환되거나 클로로, 플루오로, 브로모, 메틸, 에틸, 프로필, 이소프로필, 부틸, 이소부틸, 메틸옥시카보닐, 에틸옥시카보닐, 프로필옥시카보닐, 부틸옥시카보닐, t-부틸옥시카보닐 및 다이옥솔라닐로 이루어지는 군으로부터 선택되는 1종 이상으로 치환된 C5-C12 단일 또는 이중고리의 헤테로아릴; 비치환되거나 클로로, 플루오로, 브로모, 메틸, 에틸, 프로필, 이소프로필, 부틸 및 이소부틸로 이루어지는 군으로부터 선택되는 1종 이상으로 치환된 C5-C6 헤테로시클로알킬; 또는 비치환되거나 클로로, 플루오로, 브로모, 니트로, 메틸, 에틸, 프로필, 이소프로필, 부틸 및 이소부틸로 이루어지는 군으로부터 선택되는 1종으로 치환된 C5-C6 아릴 C1-C6의 직쇄 또는 측쇄 알킬이고, 여기서, 상기 헤테로아릴 및 헤테로시클로알킬은 고리 내 N, O 및 S로 이루어지는 군으로부터 선택되는 1종 이상의 헤테로 원자를 포함하는 것을 특징으로 하는 신규한 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체 또는 이의 약학적으로 허용가능한 염.
- 제1항에 있어서,상기 R은 메틸; 에틸; 프로필; 이소프로필; 시클로프로필; 시클로헥실; 비치환되거나 클로로, 플루오로, 메틸, 메톡시 및 트리플루오로메톡시로 이루어지는 군으로부터 선택되는 1종 이상으로 치환된 페닐; 비치환되거나 메틸, 메틸옥시카보닐(메틸에스테르) 및 다이옥솔라닐로 이루어지는 군으로부터 선택되는 1종 이상으로 치환된 티오펜, 티아졸, 퓨란, 이미다졸, 피리딘, 디하이드로벤조퓨란, 벤조퓨란, 크로만, 벤조티아졸, 인돌 또는 피라졸; 몰폴린; 또는 니트로로 치환된 페닐메틸인 것을 특징으로 하는 신규한 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체 또는 이의 약학적으로 허용가능한 염.
- 제1항에 있어서, 상기 화학식 1로 표시되는 화합물은(1) N-(2,4-디플로로-3-(3-(9-(테트라히드로-2H-피란-2-일)-9H-푸린-6-일)피리딘-2-일아미노)페닐)프로판-2-술폰아미드;(2) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-3-(트리플로로메틸)벤젠술폰아미드;(3) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-4-(트리플로로메틸)벤젠술폰아미드;4) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)싸이오펜-2-술폰아미드;(5) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)프로판-1-술폰아미드;(6) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-3,4-디클로로벤젠술폰아미드;(7) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)벤조푸란-2-술폰아미드;(8) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-4-클로로-2-플로로벤젠술폰아미드;(9) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-1-(2-니트로페닐)메탄술폰아미드;(10) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-3,4-디메톡시벤젠술폰아미드;11) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)시클로헥산술폰아미드;(12) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-4-(트리플로로메톡시)벤젠술폰아미드;13) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-4-플로로-2-(트리플로로메틸)벤젠술폰아미드;(14) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-3-클로로-2-메틸벤젠술폰아미드;(15) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)푸란-2-술폰아미드;(16) 메틸-3-(N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)술파모일)씨오펜-2-카프복실에이트;(17) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)씨오펜-3-술폰아미드;(18) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)푸란-3-술폰아미드;(19) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)시클로프로판술폰아미드;(20) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-2,4-디메틸씨아졸-5-술폰아미드;(21) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)모르포린-4-술폰아미드;(22) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-1-메틸-1H-이미다졸-4-술폰아미드;(23) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-5-메틸퓨란-2-술폰아미드;(24) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-5-(1,3-다이옥솔란-2-일)퓨란-2-술폰아미드;(25) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-2,5-다이메틸퓨란-3-술폰아미드;(26) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-5-메틸-2-(트리플루오로메틸)퓨란-3-술폰아미드;(27) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-2-클로로-6-메틸벤젠술폰아미드;(28) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-3-클로로-4-플로로벤젠술폰아미드;(29) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-3-클로로-2-플로로벤젠술폰아미드;(30) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)피리딘-3-술폰아미드;(31) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-2-메틸벤젠술폰아미드;(32) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-2-클로로벤젠술폰아미드;(33) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-3-클로로벤젠술폰아미드;(34) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-2,3-클로로벤젠술폰아미드;(35) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)벤젠술폰아미드;(36) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-2,3-디하이드로벤조푸란-7-술폰아미드;(37) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)벤조푸란-7-술폰아미드;(38) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)크로만-8-술폰아미드;(39) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-2-메틸벤조[d]싸이아졸-6-술폰아미드;(40) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-1-메틸-1H-인돌-5-술폰아미드;(41) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-1-메틸-1H-인돌-4-술폰아미드;(42) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐) -1-메틸-1H-인돌-7-술폰아미드;(43) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-1-메틸-1H-피라졸-4-술폰아미드; 및(44) N-(3-(3-(9H-푸린-6-일)피리딘-2-일아미노)-2,4-디플로로페닐)-5-클로로싸이오펜-4-술폰아미드로 이루어진 군으로부터 선택되는 어느 하나인 것을 특징으로 하는 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체 또는 이의 약학적으로 허용가능한 염.
- 제5항에 있어서, 상기 염기는 리튬(비스트리메틸실릴)아미드이고 상기 용매는 테트라하이드로퓨란인 것을 특징으로 하는 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체의 제조방법.
- 제7항에 있어서, 상기 염기는 피리딘이고 상기 용매는 디클로로메탄임을 특징으로 하는 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체의 제조방법.
- 제1항 내지 제4항 중 어느 한 항의 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 것을 특징으로 하는 Raf 키나제의 과활성에 의해 유발되는 질환의 예방 또는 치료용 약학적 조성물.
- 제9항에 있어서, 상기 Raf 키나제의 과활성에 의해 유발되는 질환은 암인 것을 특징으로 하는 약학적 조성물.
- 제10항에 있어서, 상기 암은 흑색종, 대장암, 전립선암, 갑상선암 및 난소암인 것을 특징으로 하는 약학적 조성물.
- 제1항 내지 제4항 중 어느 한 항의 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 것을 특징으로 하는 Raf 키나제의 과활성에 의해 유발되는 질환의 예방 또는 개선용 건강식품 조성물.
- 제12항에 있어서, 상기 Raf 키나제의 과활성에 의해 유발되는 질환은 암인 것을 특징으로 하는 건강식품 조성물.
- 제13항에 있어서, 상기 암은 흑색종, 대장암, 전립선암, 갑상선암 또는 난소암인 것을 특징으로 하는 건강식품 조성물.
- 제1항 내지 제4항 중 어느 한 항의 화학식 1로 표시되는 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체 또는 이의 약학적으로 허용가능한 염을 이를 필요하는 환자에게 투여하는 단계를 포함하는 Raf 키나제의 과활성에 의해 유발되는 질환의 예방 또는 치료방법.
- Raf 키나제의 과활성에 의해 유발되는 질환의 예방 또는 치료에 사용되는 제1항 내지 제4항 중 어느 한 항의 화학식 1로 표시되는 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체 또는 이의 약학적으로 허용 가능한 염.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2011337461A AU2011337461B2 (en) | 2010-12-02 | 2011-11-25 | Novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against Raf kinase, containing same as active ingredient |
CN201180066781.9A CN103339132B (zh) | 2010-12-02 | 2011-11-25 | 嘌呤基吡啶基氨基‑2,4‑二氟苯基磺酰胺衍生物、其药学上可接受的盐、其制备方法及包含其作为活性成分的对Raf激酶具有抑制活性的药物组合物 |
EP11844745.7A EP2647637B1 (en) | 2010-12-02 | 2011-11-25 | Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against raf kinase, containing same as active ingredient |
ES11844745.7T ES2562010T3 (es) | 2010-12-02 | 2011-11-25 | Derivado de purinilpiridinilamino-2,4-difluorofenilsulfonamida, sal farmacéuticamente aceptable del mismo, método de preparación del mismo y composición farmacéutica con actividad inhibidora contra cinasa Raf, que contiene el mismo como ingrediente activo |
PL11844745T PL2647637T3 (pl) | 2010-12-02 | 2011-11-25 | Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf |
CA2820550A CA2820550C (en) | 2010-12-02 | 2011-11-25 | Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative with inhibitory activity against raf kinase |
RU2013129993/04A RU2550038C2 (ru) | 2010-12-02 | 2011-11-25 | Новое производное пуринилпиридиниламино-2,4-дифторфенилсульфонамида, его фармацевтически приемлемая соль, способ его получения и фармацевтическая композиция, обладающая ингибирующей активностью в отношении raf-киназы, содержащая данное соединение в качестве активного ингредиента |
US13/990,910 US9216981B2 (en) | 2010-12-02 | 2011-11-25 | Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against Raf kinase, containing same as active ingredient |
JP2013541920A JP5689182B2 (ja) | 2010-12-02 | 2011-11-25 | 新規なピュリニルピリジニルアミノ−2,4−ジフルオロフェニルスルホンアミド誘導体、その薬学的に許容可能な塩、その製造方法及びそれを有効成分として含むRafキナーゼの阻害活性を有する薬学的組成物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20100122047 | 2010-12-02 | ||
KR10-2010-0122047 | 2010-12-02 | ||
KR10-2011-0124360 | 2011-11-25 | ||
KR1020110124360A KR101364658B1 (ko) | 2010-12-02 | 2011-11-25 | 신규한 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 Raf키나제의 저해활성을 가지는 약학적 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012074249A2 true WO2012074249A2 (ko) | 2012-06-07 |
WO2012074249A3 WO2012074249A3 (ko) | 2012-08-23 |
Family
ID=46172371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/009091 WO2012074249A2 (ko) | 2010-12-02 | 2011-11-25 | 신규한 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 Raf키나제의 저해활성을 가지는 약학적 조성물 |
Country Status (11)
Country | Link |
---|---|
US (1) | US9216981B2 (ko) |
EP (1) | EP2647637B1 (ko) |
JP (1) | JP5689182B2 (ko) |
KR (1) | KR101364658B1 (ko) |
CN (1) | CN103339132B (ko) |
AU (1) | AU2011337461B2 (ko) |
CA (1) | CA2820550C (ko) |
ES (1) | ES2562010T3 (ko) |
PL (1) | PL2647637T3 (ko) |
RU (1) | RU2550038C2 (ko) |
WO (1) | WO2012074249A2 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013071865A1 (en) * | 2011-11-14 | 2013-05-23 | Centaurus Biopharma Co., Ltd. | Kinase modulating compounds, compositions containing the same and use thereof |
CN103387576A (zh) * | 2013-08-09 | 2013-11-13 | 中国药科大学 | 基于嘌呤结构的芳酰胺类Raf激酶抑制剂及其制备方法和用途 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103102349B (zh) * | 2011-11-14 | 2017-03-15 | 北京赛林泰医药技术有限公司 | 蛋白激酶抑制剂及其组合物和用途 |
WO2017121379A1 (zh) * | 2016-01-15 | 2017-07-20 | 北京赛林泰医药技术有限公司 | 一种调节激酶化合物的对甲苯磺酸盐及其结晶 |
SG11201806596TA (en) * | 2016-02-03 | 2018-09-27 | Samjin Pharmaceutical Co Ltd | Pyridine derivative inhibiting raf kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof |
CA2969295A1 (en) * | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor |
JP7394768B2 (ja) * | 2017-09-20 | 2023-12-08 | エイビーエム セラピューティックス コーポレイション | キナーゼ阻害剤としての環状イミノピリミジン誘導体 |
JP7247557B2 (ja) | 2018-11-30 | 2023-03-29 | 株式会社リコー | 回路基板、回路基板の製造方法、撮像装置 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
WO2005113494A2 (en) * | 2004-05-07 | 2005-12-01 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
WO2006101783A2 (en) * | 2005-03-15 | 2006-09-28 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
WO2007092531A2 (en) * | 2006-02-06 | 2007-08-16 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
EP2170887A2 (en) | 2007-06-07 | 2010-04-07 | Amgen Inc. | Heterocyclic compounds as raf kinase modulators |
UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
CN103974954B (zh) * | 2011-11-14 | 2016-08-24 | 北京赛林泰医药技术有限公司 | 调节激酶的化合物、含有它们的组合物及其用途 |
-
2011
- 2011-11-25 JP JP2013541920A patent/JP5689182B2/ja active Active
- 2011-11-25 WO PCT/KR2011/009091 patent/WO2012074249A2/ko active Application Filing
- 2011-11-25 CN CN201180066781.9A patent/CN103339132B/zh active Active
- 2011-11-25 EP EP11844745.7A patent/EP2647637B1/en active Active
- 2011-11-25 ES ES11844745.7T patent/ES2562010T3/es active Active
- 2011-11-25 KR KR1020110124360A patent/KR101364658B1/ko active IP Right Grant
- 2011-11-25 CA CA2820550A patent/CA2820550C/en active Active
- 2011-11-25 US US13/990,910 patent/US9216981B2/en active Active
- 2011-11-25 AU AU2011337461A patent/AU2011337461B2/en not_active Ceased
- 2011-11-25 PL PL11844745T patent/PL2647637T3/pl unknown
- 2011-11-25 RU RU2013129993/04A patent/RU2550038C2/ru active
Non-Patent Citations (9)
Title |
---|
BIOCHIM. BIOPHYS. ACTA., vol. 1653, 2003, pages 25 - 40 |
BIOLOGY OF THE CELL, vol. 93, 2001, pages 53 - 62 |
CANCER RES., vol. 63, 2003, pages 5198 - 5202 |
CANCER RES., vol. 64, 2004, pages 2338 - 2342 |
EXP. CELL. RES., vol. 253, 1999, pages 34 - 46 |
NATURE REV. MOL. CELL BIOLOGY, vol. 5, 2004, pages 875 - 885 |
NATURE REV. MOL. CELL. BIOL., vol. 5, 2004, pages 875 - 885 |
NATURE, vol. 417, 2002, pages 949 - 954 |
See also references of EP2647637A4 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013071865A1 (en) * | 2011-11-14 | 2013-05-23 | Centaurus Biopharma Co., Ltd. | Kinase modulating compounds, compositions containing the same and use thereof |
US9550781B2 (en) | 2011-11-14 | 2017-01-24 | Centaurus Biopharma Co., Ltd. | Kinase modulating compounds, compositions containing the same and use thereof |
CN103387576A (zh) * | 2013-08-09 | 2013-11-13 | 中国药科大学 | 基于嘌呤结构的芳酰胺类Raf激酶抑制剂及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN103339132A (zh) | 2013-10-02 |
RU2550038C2 (ru) | 2015-05-10 |
EP2647637A4 (en) | 2013-11-20 |
RU2013129993A (ru) | 2015-01-10 |
EP2647637A2 (en) | 2013-10-09 |
KR101364658B1 (ko) | 2014-02-19 |
ES2562010T3 (es) | 2016-03-02 |
KR20120060744A (ko) | 2012-06-12 |
US20130317023A1 (en) | 2013-11-28 |
JP5689182B2 (ja) | 2015-03-25 |
CA2820550C (en) | 2016-02-23 |
US9216981B2 (en) | 2015-12-22 |
PL2647637T3 (pl) | 2016-06-30 |
AU2011337461B2 (en) | 2015-04-02 |
WO2012074249A3 (ko) | 2012-08-23 |
EP2647637B1 (en) | 2016-02-03 |
CA2820550A1 (en) | 2012-06-07 |
CN103339132B (zh) | 2017-02-15 |
JP2013545768A (ja) | 2013-12-26 |
AU2011337461A1 (en) | 2013-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012074249A2 (ko) | 신규한 퓨리닐피리디닐아미노-2,4-디플루오로페닐 설폰아미드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 Raf키나제의 저해활성을 가지는 약학적 조성물 | |
WO2017160116A2 (ko) | 니코틴아미드 포스포리보실트랜스퍼라제 억제용 신규 화합물 및 이를 포함하는 조성물 | |
WO2018004213A1 (ko) | Smo 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물 | |
WO2018139903A1 (ko) | 피리미딘 화합물 및 그의 의약 용도 | |
WO2017188694A1 (ko) | 질소를 포함하는 헤테로아릴 화합물 및 이의 용도 | |
WO2018088749A1 (ko) | 신규한 피리미딘화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암 및 염증질환의 예방 또는 치료용 약학적 조성물 | |
WO2015099392A1 (ko) | 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물 | |
EP2906558A1 (en) | Sodium channel blockers, preparation method thereof and use thereof | |
WO2009125923A2 (en) | Novel indol carboxylic acid bispyridyl carboxamide derivatives, pharmaceutically acceptable salt thereof, preparation method and composition containing the same as an active ingredient | |
WO2021125803A1 (ko) | 신규한 피리미딘 유도체 및 이의 용도 | |
WO2018062978A1 (ko) | 신규 헤테로아릴 화합물, 이의 거울상 이성질체, 부분 입체 이성질체 또는 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 항바이러스용 조성물 | |
WO2014109530A1 (ko) | 2-(페닐에티닐)티에노[3,4-b]피라진 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
WO2018004263A1 (ko) | 광학 활성 피라노크로메닐페놀 유도체 및 그를 포함하는 약학적 조성물 | |
WO2017135589A1 (ko) | 라프 키나제 및 혈관내피성장인자 수용체를 저해하는 피리딘 유도체, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이의 용도 | |
WO2020036386A1 (ko) | 이소인돌린-1온 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
WO2014030972A1 (ko) | 항암용 조성물 | |
WO2011105643A1 (ko) | 퍼록시솜 증식자 활성화 수용체 리간드 셀레나졸 유도체, 이의 제조방법 및 이들 화합물의 용도 | |
WO2009093872A2 (ko) | 신규한 디아민 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 암 치료용 약학 조성물 | |
WO2020096416A1 (ko) | Yap-tead 결합을 저해하는 화합물 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약제학적 조성물 | |
WO2019194583A1 (ko) | 3-페닐-2,8-디히드로피라노[2,3-f]크로멘 유도체 및 이를 포함하는 약학적 조성물 | |
WO2020013531A1 (ko) | N-(3-(이미다조[1,2-b]피리다진-3-일에티닐)-4-메틸페닐)-5-페닐-4,5-다이하이드로-1H-피라졸-1-카복사마이드 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 | |
WO2021187766A1 (ko) | P38 제거능을 갖는 화합물, 이의 제조방법 및 이를 포함하는 만성 염증성 질환 치료용 조성물 | |
WO2021101268A1 (ko) | 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 | |
WO2019212256A1 (ko) | 신규한 헤테로 사이클 유도체 | |
WO2020060112A1 (en) | Novel thiazole derivatives and pharmaceutically acceptable salts thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11844745 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2820550 Country of ref document: CA Ref document number: 2013541920 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011844745 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013129993 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2011337461 Country of ref document: AU Date of ref document: 20111125 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13990910 Country of ref document: US |